title: [A population-based study of need for changes and continuing rates of antihypertensive drugs].
abstract: BACKGROUND
  Antihypertensive drugs are frequently changed because of inefficacy and adverse effects. The aim of this study was to compare the incidence of changes of the new classes of drugs from the classical beta-blockers and diuretics. We also have calculated the probability of continuing with each class of drug.
  
  
  METHODS
  Clinical reports of hypertensive patients of a general practice centre were examined. All changes of treatment and their causes were registered between october 1997 and september 1999. The incidences for global changes and also for intolerance and inefficacy changes were calculated for each drug. Relative risks for beta-blockers, diuretics, ACE inhibitors of anhidride carbonic enzyme and angiotensine II-receptor-antagonists were analized. The cumulated probability for continuing therapy was also studied.
  
  
  RESULTS
  27.6% out of 786 courses of treatment were changed, 51.4% due to intolerance and 29,8% due to inefficacy. The probability for continuing was 88% after 3 months, 81% after 6 months, 71% after one year and 54% after 2 years. The probability for discontinuing because of intolerance was higher in the first 3 months (51%), but afterwards it remained stable along the time.
  
  
  CONCLUSIONS
  Antihypertensive drugs are discontinued more frequently than what it would be desirable and their continuing rates are low. Differences observed among each class of drugs are not argument enough for changing the general recommendation of using beta-blockers and diuretics as first choice drugs for initial treatment of hypertension.
authors.affiliation: Centro de Salud Prosperidad. Hospital La Princesa. Area II. Madrid.
authors.forename: F
authors.initials: F
authors.lastname: Javier Sierra Alonso
authors.forename: C
authors.initials: C
authors.lastname: Lagarejos Tricas
authors.forename: F
authors.initials: F
authors.lastname: Cirujano Pita
authors.forename: N
authors.initials: N
authors.lastname: Villalba Guijorro
authors.forename: M
authors.initials: M
authors.lastname: Jesús Muñoz Sanz
authors.forename: F
authors.initials: F
authors.lastname: Rodríguez Salvanés
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use; D004363:Drug Utilization; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012306:Risk; D013030:Spain
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004232:Diuretics